Bruce Booth is an early stage venture capitalist at Atlas Venture who enjoys working with great scientists and entrepreneurs to start new biotech companies. Atlas focuses on seed-stage venture creation around the discovery and development of novel therapeutics. Since joining Atlas in 2005, Bruce has been involved in the founding and funding a number of innovative companies, with a particular focus on capital efficient models for drug R&D.
It seems very likely that the demand for innovative products and pipeline will accelerate in the coming years in order to support the revenue needs of larger commercial-stage companies.
With the Cancer Moonshot initiative in the spotlight today, here are some insights to consider in the race to develop immuno-oncology drugs.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Beyond being a revolutionary research tool, CRISPR/Cas9 also holds enormous potential for changing medicine, and this has certainly attracted the attention of the business and investor community in biotech.
Fundamentally, my biggest concern with the new rules regards the importance of predictability in business. Strategic planning, essential to running sustainable enterprises, requires the predictability of transparent and forward-looking laws, along with proper due process and accountability.
Of the 142 IPOs since January 2013, 74 percent of them are below their IPO prices.
The biotech markets have softened. What's the state of the forthcoming biotech IPO? Atlas Venture's Bruce Booth weighs in.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
The big question, though, is whether this cycle, in place since the bottom in 2009, is truly unique or special relative to past investment cycles, and how that might affect its sustainability.
Here are the “seven habits”, or more aptly just attributes, of Celgene’s highly successful external R&D strategy.